Bruker Cellular Analysis / Blog / Antibody Discovery / Maximizing Monoclonal Antibody Success: Building a Foundation of B Cell Diversity

Maximizing Monoclonal Antibody Success: Building a Foundation of B Cell Diversity


In the rapidly changing landscape of antibody discovery, researchers encounter significant challenges that necessitate inventive solutions. In a new on-demand webinar, we explore these obstacles and share an advanced approach to remain at the forefront of cutting-edge research capabilities.

Current Challenges in Antibody Discovery

  1. Expanding Target Complexity: Traditional targets like GPCR and ion channels are no longer the only focus. New, highly homologous, toxic, and low immunogenicity targets pose challenges in developing target-specific antibodies.
  2. Evolving Requirements for Antibody Characteristics: As therapeutics and diagnostics advance, the demand for antibodies with specific characteristics rises. Factors such as cross-reactivity, strain specificity, and affinity require intensive effort for characterization.
  3. Cost and Time Pressures: The biotech industry faces economic challenges, necessitating a reduction in campaign costs and durations from target identification to lead optimization.

Navigating Industry Challenges with the Opto® B Discovery Workflow

Bruker’s Opto B Discovery workflow on the Beacon® system provides features and compatibilities adaptable to diverse campaigns, focusing on high-performance antibody discovery from B cells derived from mice, rabbits, and humans.

Researchers can customize workflows based on animal species and B cell repertoire, screening throughput, assay types, and other variables. This flexibility enables researchers to design bespoke workflows that align with their specific requirements.

Exploring Broad Sequence Diversity

In an internal study, researchers aimed to broaden species diversity for increased campaign success. Memory B cells from seven species were explored, each with unique properties:

  • Mice and rats for robust plasma cell isolation
  • Camelids for single-chain nanobodies
  • Chickens, cow, goat, and sheep for immunogenicity challenges

To test the versatility of existing kits, human and rabbit sample prep kits were utilized for off-label use in different species. While mice and rats demonstrated promising results, alpaca showed potential. Further optimization is underway for chicken, alpaca, and bovine samples, while goat and sheep usage requires additional refinement.

Ready to delve deeper into the Opto® B Discovery Workflow and gain insights into overcoming your research challenges? Watch our recent on-demand webinar for an in-depth exploration.

Share This Article